The red fruit juice found to cause rhabdomyolysis when mixed with statins
One drink may spell trouble when combined with medication used for high blood pressure, cholesterol and depression. (Source: Daily Express - Health)
Source: Daily Express - Health - March 10, 2023 Category: Consumer Health News Source Type: news
Physician Reminders May Boost Statin Prescribing: PCDS Physician Reminders May Boost Statin Prescribing: PCDS
Although high-intensity statin use increased when clinicians received prescribing reminders, 31% of those receiving reminders dropped out of the trial, suggesting that alert fatigue remains a concern.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2023 Category: Consumer Health News Tags: Cardiology News Source Type: news
'Comparable to statins': The type of milk that could significantly lower cholesterol
Research suggests the main ingredient in this milk could lower high cholesterol by a whopping 70 percent. (Source: Daily Express - Health)
Source: Daily Express - Health - March 9, 2023 Category: Consumer Health News Source Type: news
Is Bempedoic Acid the CLEAR Answer to Statin Intolerance? Is Bempedoic Acid the CLEAR Answer to Statin Intolerance?
Cardiologists Michelle O ’Donoghue and Ann Marie Navar discuss the CLEAR Outcomes trial on Bempedoic acid in patients at high CV risk with statin intolerance and where this drug may fit in the lipid lowering arsenal.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2023 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
ACC: Treat-to-Target LDL-C Strategy Noninferior to High-Intensity Statins
TUESDAY, March 7, 2023 -- For patients with coronary artery disease, a treat-to-target low-density lipoprotein cholesterol (LDL-C) strategy is noninferior to high-intensity statin therapy, according to a study published online March 6 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2023 Category: Pharmaceuticals Source Type: news
Statin Users Show LDL Doesn't Come Close to Telling Whole Story of ASCVD
(MedPage Today) -- NEW ORLEANS -- It was inflammation, not cholesterol per se, that was the bigger contributor to residual cardiovascular risk on statin therapy, according to a large meta-analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 7, 2023 Category: Cardiology Source Type: news
ACC: Bempedoic Acid Cuts Cardiovascular Event Risk in Statin-Intolerant
MONDAY, March 6, 2023 -- Treatment with bempedoic acid is associated with a lower risk for major adverse cardiovascular events among statin-intolerant patients, according to a study published online March 4 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 6, 2023 Category: Pharmaceuticals Source Type: news
Movers & Shakers: China stocks slip after growth target released, as Ciena shares pop on earnings beat
Here are some of the most active premarket movers on Monday. U.S. stock futures ES00, pointed to a slow start after a two-day rally. Alibaba’s U.S.-listed stock BABA, fell by 1%, as did the KraneShares CSI China Internet ETF KWEB, , after China’s official 5% growth target was deemed underwhelming.…#kraneshares #etfkweb #statin #kbhome #kbh #jpmorgan #drhortondhi #meritagehomesmth #michaelrehaut #norfolksoutherncorp (Source: Reuters: Health)
Source: Reuters: Health - March 6, 2023 Category: Consumer Health News Source Type: news
Nexletol Could Be Alternative Cholesterol Med for Folks Who Can't Take Statins
MONDAY, March 6, 2023 -- Not everyone can tolerate statins to reduce their high cholesterol, but now a new study finds the medication bempedoic acid (Nexletol) reduced the combined rate of bad cardiovascular events by 13%. “We’re very pleased... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 6, 2023 Category: General Medicine Source Type: news
New heart attack 'risk calculators' could help prescribe statins to patients most in need
A study of thousands of people showed the tools were two-and-a-half times more effective at administering the most appropriate treatment for patients. (Source: Daily Express - Health)
Source: Daily Express - Health - March 5, 2023 Category: Consumer Health News Source Type: news
Atorvastatin Cut Anthracycline Cardiac Dysfunction Atorvastatin Cut Anthracycline Cardiac Dysfunction
A daily 40-mg dose of atorvastatin for 12 months significantly cut incident cardiac dysfunction in patients with lymphoma receiving anthracycline treatment.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 5, 2023 Category: Cancer & Oncology Tags: Cardiology News Source Type: news
Doctors hail NHS approved pill that slashes risk of heart attacks for those who can't take statins
Bempedoic acid, was approved for NHS use last year after promising early data showed it cut cholesterol by up to 25%. Peter Eggle (pictured), 73, has used it for 18 months and feels 'fantastic'. (Source: the Mail online | Health)
Source: the Mail online | Health - March 4, 2023 Category: Consumer Health News Source Type: news
Study suggests bempedoic acid reduces cholesterol, risk of heart attack
Bempedoic acid taken alone reduces cholesterol and heart attacks in patients who can ' t tolerate statins, according to a clinical research published Saturday in New England Journal of Medicine.. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 4, 2023 Category: Consumer Health News Source Type: news
A potential statin alternative shows promise to help heart health
Bempedoic acid may be an alternative for people who need to lower their cholesterol but can't or won't take statins, according to a large study published Saturday in the New England Journal of Medicine. (Source: CNN.com - Health)
Source: CNN.com - Health - March 4, 2023 Category: Consumer Health News Source Type: news
Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients Bempedoic Acid Cuts CV Events in Statin-Intolerant Patients
The CLEAR Outcomes trial establishes this new drug as an important addition to available nonstatin LDL-lowering therapies, experts say.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 4, 2023 Category: Endocrinology Tags: Cardiology News Source Type: news
